Trial Profile
An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810, Given Orally as Single Agent to Patients With Advanced Solid Tumours
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Lucitanib (Primary)
- Indications Solid tumours; Thymic epithelial tumour
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Clovis Oncology Italy; EOS S.p.A.; Servier
- 18 Jul 2022 Results of a Pop PK pooled analysis from five phase 1 and 2 clinical studies: NCT01283945, NCT02053636, ISRCTN23201971, NCT02202746 and NCT02109016 published in the European Journal of Drug Metabolism and Pharmacokinetics
- 12 May 2017 Status changed from active, no longer recruiting to completed.
- 11 Mar 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Sep 2016, as reported by ClinicalTrials.gov.